| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/10/2002 | US6447772 Compositions and methods relating to reduction of symptoms of autism |
| 09/10/2002 | US6447771 Methods and materials relating to novel CD39-like polypeptides |
| 09/10/2002 | US6447769 Modified tumor cells to inhibit transforming growth factor |
| 09/10/2002 | US6447768 Methods of gene therapy with a DNA sequence encoding NOS |
| 09/10/2002 | US6447766 Deamidated chemokines |
| 09/10/2002 | US6447750 Medicinal aerosol formulation |
| 09/10/2002 | CA2288375C Novel pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| 09/10/2002 | CA2258661C Synthetic phosphopeptides for treating bone diseases |
| 09/10/2002 | CA2239159C Acylated enol derivatives of .alpha.-ketoesters and .alpha.-ketoamides |
| 09/10/2002 | CA2129339C Inhibitors of thrombosis |
| 09/10/2002 | CA2108678C Production of phosphopeptides from casein |
| 09/10/2002 | CA2083171C Antasthmatic |
| 09/08/2002 | CA2370324A1 Large circular target-specific antisense nucleic acid compounds |
| 09/06/2002 | WO2002069232A2 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| 09/06/2002 | WO2002068690A1 Antisense modulation of wrn expression |
| 09/06/2002 | WO2002068688A1 Antisense modulation of calreticulin expression |
| 09/06/2002 | WO2002068687A2 Function and application of tob gene in central nervous system of mammal |
| 09/06/2002 | WO2002068680A2 Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes |
| 09/06/2002 | WO2002068676A2 METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING |
| 09/06/2002 | WO2002068673A2 Hin-1, a tumor suppressor gene |
| 09/06/2002 | WO2002068672A2 Antisense modulation of recql4 expression |
| 09/06/2002 | WO2002068660A1 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture |
| 09/06/2002 | WO2002068657A2 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof |
| 09/06/2002 | WO2002068655A1 Method of searching for remedy for hepatitis d |
| 09/06/2002 | WO2002068654A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/06/2002 | WO2002068652A2 Nov-x proteins and nucleic acids encoding same |
| 09/06/2002 | WO2002068650A2 Modified and stabilized gdf propeptides and uses thereof |
| 09/06/2002 | WO2002068649A2 Proteins and nucleic acids encoding same |
| 09/06/2002 | WO2002068648A2 Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof |
| 09/06/2002 | WO2002068647A2 Proteins, polynucleotides encoding them and methods of using the same |
| 09/06/2002 | WO2002068643A1 Nomuraeae rileyi-origin ecdysteroid 22-oxidase and molt hormone inactivation system with the use of the same |
| 09/06/2002 | WO2002068642A1 A novel polypeptide compose substance for promoting blood and blood vessel cell growth |
| 09/06/2002 | WO2002068640A1 CELL PROLIFERATION FACTOR Fwa267 |
| 09/06/2002 | WO2002068639A1 CELL PROLIFERATION FACTOR Fwap10576 |
| 09/06/2002 | WO2002068638A1 83 human secreted proteins |
| 09/06/2002 | WO2002068637A2 Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| 09/06/2002 | WO2002068636A1 Methods and agents for modifying human angiogenesis |
| 09/06/2002 | WO2002068635A2 Methods of inhibiting expression of a target gene in mammalian cells |
| 09/06/2002 | WO2002068630A1 Methods for identifying peptides which modulate a biological process |
| 09/06/2002 | WO2002068626A2 Novel human ion channel-related proteins and polynucleotides encoding the same |
| 09/06/2002 | WO2002068620A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 09/06/2002 | WO2002068617A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | WO2002068614A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 09/06/2002 | WO2002068610A2 Compositions and methods for affecting virulence determinants in bacteria |
| 09/06/2002 | WO2002068608A2 Sulfated ccr5 peptides for hiv-1 infection |
| 09/06/2002 | WO2002068604A2 Polynucleotide encoding two novel human potassium channel beta-subunits, k+betam4 and k+betam5 |
| 09/06/2002 | WO2002068602A2 Methods for modulating g2a receptor activity |
| 09/06/2002 | WO2002068601A2 Small peptides capable of modulating the function of cd66 (ceacam) family members |
| 09/06/2002 | WO2002068595A2 Mono-and diacylglycerol acyltransferases and methods of use thereof |
| 09/06/2002 | WO2002068591A2 G-protein coupled receptor nucleic acids, polypeptides, antibodies and uses thereof |
| 09/06/2002 | WO2002068590A2 Antisense modulation of recql expression |
| 09/06/2002 | WO2002068586A2 Hiv/fiv protease inhibitors |
| 09/06/2002 | WO2002068585A2 Tip39 polypeptides |
| 09/06/2002 | WO2002068584A2 Antisense modulation of cytohesin-1 expression |
| 09/06/2002 | WO2002068582A2 Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof |
| 09/06/2002 | WO2002068476A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 09/06/2002 | WO2002068470A2 Interferon-alpha induced gene |
| 09/06/2002 | WO2002068469A2 Modified thrombopoietin with reduced immunogenicity |
| 09/06/2002 | WO2002068467A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 09/06/2002 | WO2002068466A2 Hypoxia-regulated genes |
| 09/06/2002 | WO2002068465A2 Novel p53-inducible protein |
| 09/06/2002 | WO2002068463A1 A novel natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof |
| 09/06/2002 | WO2002068461A2 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | WO2002068457A2 Antiangiogenic peptides derived from endostatin |
| 09/06/2002 | WO2002068456A1 Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs |
| 09/06/2002 | WO2002068455A2 Efficient recovery of correctly refolded proteins |
| 09/06/2002 | WO2002068446A1 Antisense modulation of talin expression |
| 09/06/2002 | WO2002068445A1 Antisense nucleic acid inhibitors of mycothiol production in mycobacterium tuberculosis |
| 09/06/2002 | WO2002068444A1 Ttk in diagnosis and as a therapeutic target in cancer |
| 09/06/2002 | WO2002068015A2 Modular infusion device and method |
| 09/06/2002 | WO2002067996A2 Beta-endorphin/crf gene therapy for locally combating pain |
| 09/06/2002 | WO2002067990A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | WO2002067989A1 Crystallisation-resistant aqueous growth hormone formulations |
| 09/06/2002 | WO2002067986A2 Symbiotic regenerative agent |
| 09/06/2002 | WO2002067981A1 Blood coagulation factor xiii for treating platelet disorders |
| 09/06/2002 | WO2002067980A1 Method for treating von willebrand's disease |
| 09/06/2002 | WO2002067979A1 Method of improving the growth performance of an animal |
| 09/06/2002 | WO2002067978A1 Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp |
| 09/06/2002 | WO2002067977A1 Eye drops |
| 09/06/2002 | WO2002067976A1 Novel ischemia/reperfusion injury inhibitors |
| 09/06/2002 | WO2002067975A1 Negative regulation of epidermal growth factor receptor activity by mig-6 |
| 09/06/2002 | WO2002067974A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis |
| 09/06/2002 | WO2002067973A1 Compositions and methods for protecting tissues and cells from damage, and for repairing damaged tissues |
| 09/06/2002 | WO2002067972A1 Method of inducing vitreous detachment |
| 09/06/2002 | WO2002067971A2 Use of endostatin in the treatment of ocular neovascularization |
| 09/06/2002 | WO2002067970A1 TRYPTOPHANYL-tRNA SYNTHETASE DERIVED POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 09/06/2002 | WO2002067969A2 Stabilized insulin formulations |
| 09/06/2002 | WO2002067968A2 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 09/06/2002 | WO2002067967A2 Method of treating rhinitis or sinusitis |
| 09/06/2002 | WO2002067959A1 Peptide derived from yeast having activities as anti-tsress, anti-fatigue and brain neurotrophic factor and relaxing premenstrual syndrome and menstrual pain, and prepairing process thereof |
| 09/06/2002 | WO2002067958A1 Method for determining efficacy of reverse cholesterol transport enhancing agents |
| 09/06/2002 | WO2002067957A1 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
| 09/06/2002 | WO2002067954A2 Use of particulate biocomplex bk-riv for producing a medicament for protecting and reconstructing the hepatic parenchyma |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067910A2 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
| 09/06/2002 | WO2002067907A1 Compositions and methods for preventing platelet aggregation |
| 09/06/2002 | WO2002067904A1 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer |
| 09/06/2002 | WO2002067902A2 Modulation of release from dry powder formulations |
| 09/06/2002 | WO2002067901A1 Fibrate-statin combinations with reduced fed-fasted effects |
| 09/06/2002 | WO2002067897A2 In-situ gel formation of pectins |